Cannabis Legalization and Opioid Deaths: What the Evidence Shows
A study published in the Southern Economic Journal found that states adopting recreational cannabis laws experienced lower opioid overdose death rates, but the result should be interpreted as an association rather than definitive proof that legalization caused the decline.
The research, “Because I Got High? Recreational Marijuana Legalization’s Impact on Opioid Overdose Deaths”, examined state-level data using event studies and a difference-in-differences model adapted from methods developed by Callaway and Sant’Anna. The researchers reported an estimated reduction of approximately 3.5 opioid overdose deaths per 100,000 people after recreational marijuana legalization.
The analysis also found that the relationship appeared stronger in states that legalized recreational cannabis earlier. That pattern may indicate that effects emerge gradually as legal markets open, dispensaries become available and consumers become more familiar with the products. It could also reflect differences between early- and late-adopting states that are unrelated to cannabis policy.
Why researchers are studying cannabis and opioid deaths
The possibility that cannabis might substitute for prescription opioids has attracted attention throughout the opioid crisis. Some people with chronic pain report using cannabis in place of opioid medications, and earlier studies have linked medical cannabis dispensaries with lower opioid prescribing or overdose rates.
But those findings have not been consistent. Cannabis legalization does not directly treat opioid use disorder, and it has not been established as a replacement for evidence-based medications such as buprenorphine, methadone or naltrexone. The National Institute on Drug Abuse describes medications for opioid use disorder as safe and effective treatments that can reduce illicit opioid use and improve health outcomes.
Legalization also involves more than simply changing possession laws. The timing of commercial sales, the number of operating dispensaries, product availability and the characteristics of people who use legal cannabis can all affect outcomes. Those differences make it difficult to isolate the effect of legalization from broader changes in drug markets, healthcare access and state policy.
What the study did—and did not—show
The study used observational state-level data rather than a randomized experiment. Its statistical approach was designed to address a common problem in legalization research: states adopt cannabis laws at different times, and the effects may vary across states or develop over time.
Even with those adjustments, the results cannot establish that recreational cannabis legalization alone caused opioid deaths to fall. States that legalized cannabis may have differed from other states in economic conditions, healthcare systems, harm-reduction programs, prescribing practices or exposure to illicit fentanyl. State-level data also cannot show whether individual opioid users actually replaced opioids with cannabis.
The researchers acknowledged that their analysis focused on fatal overdoses and did not measure nonfatal overdoses, hospitalizations, individual treatment histories or changes in opioid use by specific patient groups. The study also could not fully account for the scale of legal cannabis markets in each state.
Evidence remains mixed
Other research has reached different conclusions. A 2024 study in JAMA Health Forum, which analyzed cannabis law implementation from 2006 through 2020 while accounting for staggered policies and other opioid laws, found no statistically significant association between recreational cannabis legalization and overall opioid mortality. It did find a possible reduction in deaths involving synthetic opioids, but the authors urged caution because the estimate was based on a limited number of treated states and data quality varied by opioid type.
A broader systematic review of studies on state cannabis laws and opioid outcomes likewise concluded that findings on recreational cannabis and overdose deaths are inconsistent. The review found no reliable evidence that cannabis legalization reduces opioid use disorder and warned that legalization should not currently be viewed as an established strategy for curbing the opioid epidemic.
For readers tracking the crisis, the Centers for Disease Control and Prevention’s overview of the opioid epidemic provides current background on the changing waves of opioid-involved deaths, including the central role of illegally manufactured fentanyl in recent years.
The study adds to an important policy debate, but it does not settle it. Cannabis legalization may influence opioid outcomes in some settings, particularly where it expands access to regulated products, yet the size and direction of that effect remain uncertain. More research using individual-level data, longer follow-up periods and measures of nonfatal overdose and treatment access will be needed before cannabis policy can be considered a dependable tool for reducing opioid-related deaths.
